| (Values in U.S. Thousands) | Dec, 2020 | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 |
| Sales | 148,220 | 137,050 | 121,300 | 120,630 | 109,080 |
| Sales Growth | +8.15% | +12.98% | +0.56% | +10.59% | +19.91% |
| Net Income | -29,150 | -12,190 | -8,830 | -7,970 | -24,950 |
| Net Income Growth | -139.13% | -38.05% | -10.79% | +68.06% | -81.32% |
Gw Pharma ADR (GWPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
Fiscal Year End Date: 12/31